Pharmaceutical giants Johnson & Johnson, Eli Lilly, and Pfizer are following in each other’s footsteps by investing heavily in U.S. manufacturing after President Donald Trump threatened major tariffs on pharmaceutical products.
Johnson & Johnson announced a $55 billion investment over the next four years, boosting its U.S. investment by 25% compared to previous investments. The healthcare giant will expand existing sites and build new ones for its medicines and medical technology business.
Eli Lilly had already made a similar commitment in February, investing $27 billion in U.S. manufacturing capacity. Pfizer followed suit in early March, promising to shift its operations to the U.S. if Trump’s tariff threat materializes.
The investments are expected to create thousands of jobs and boost the industry’s economic impact in the U.S. to an estimated $100 billion.
In contrast, AstraZeneca is looking to expand its presence in Asia, with a new R&D hub in Beijing worth $2.5 billion over five years.
Source: https://www.biospace.com/business/j-j-joins-pharma-peers-with-55b-us-manufacturing-boost-following-trumps-tariff-threats